Psilocybin approved for depression
The government has announced the 'magic mushroom' drug psilocybin will become available for patients with treatment-resistant depression. Psychiatrist, Cameron Lacey, spoke to Ingrid Hipkiss.
Tags:
To embed this content on your own webpage, cut and paste the following:
See terms of use.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Scoop
an hour ago
- Scoop
Govt Launches Suicide Prevention Plan
A five-year plan aiming to tackle New Zealand's 'stubbornly high suicide rates' has been released today. The plan includes new strategies like peer support roles for mental health patients in emergency departments, and crisis recovery cafés so people don't have to resort to a hospital and can receive care in the community. The SMC asked experts to comment. Jacqui Maguire, Registered Clinical Psychologist, comments: 'New Zealand's suicide statistics remain a source of national shame. The Government's new Suicide Prevention Action Plan signals good intent, but without meaningful detail, it is difficult to assess its true impact. 'The most obvious gap in the plan is workforce development. Peer support and coordination roles are valuable, but the plan does not outline the training and retention of psychologists, social workers and mental health nurses who are needed to meet demand. Across both public and NGO services, workforce shortages, not just budget, are a real constraint. If we do not have qualified professionals we cannot deliver the required scale of care. 'Secondly, I believe the plan could be bolder and more detailed. For example, Every emergency department should have skilled, trained support not just the 8 regions outlined. Peer support is already being trialled, including in Wellington ED, but suicide risk exists nationwide. The alcohol and suicide link is acknowledged, but there is no clear policy action mentioned. For example, will the Plan tackle outlet density or alcohol pricing? We need to ensure therapy is accessible to all. The current model excludes many middle-income earners, who fall outside subsidy thresholds and cannot afford private care. Unless you are under 25 and covered by PIKI, access can be incredibly limited. That is neither equitable nor sustainable. The plan also speaks to hope, wellbeing and prevention yet makes little reference to the deeper drivers of suicide such as loneliness, housing stress, cultural disconnection and income insecurity. If we want significant suicide reduction, these issues are central. While the plan refers to data and information sharing, it does not address the kind of infrastructure needed to enable real-time, coordinated care. Particularly between crisis services and mental health teams. Without this, continuity of care will likely remain fragmented. Advertisement - scroll to continue reading 'The plan sounds promising on paper. However without a clear picture of who is delivering what, and how services will be integrated, it is hard to see how this plan will drive the scale of change New Zealand urgently needs to meaningfully reduce suicide.' No conflict of interest declared. Anthony O'Brien, Associate Professor in Mental Health Nursing, University of Waikato, comments: 'It is encouraging to see this new action plan on suicide. There is some tension between the action areas of the plan, and other areas of policy. Some actions require no funding but have the potential to limit suicide risk. 'For example the role of alcohol is highlighted, but curbs on alcohol advertising are not suggested. There is no plan to act on the role of social media in fueling suicide risk. There is limited recognition in the plan of the increased risk of suicide among people who are not employed, despite the report identifying social determinants contributing to suicide risk. 'It is good to see recognition of how various workforces can respond to suicidal thinking and support for those bereaved by suicide. There could be more recognition of the role of primary health care. It was surprising that the Access and Choice Programme was not included in current health-led suicide prevention supports. Also absent is the role of school nurses who in addition to providing support for students experiencing distress could be mobilised as school-based champions of suicide prevention. 'Given the commitment to measurable outcomes it would have been good to see some recognition of a suicide research strategy.'
RNZ News
2 hours ago
- RNZ News
Morning Report Essentials for Thursday 19 June 2025
Pacific health 10:00 am today In today's episode, Foreign Minister Winston Peters speaks about plans to evacuate New Zealanders from Israel and Iran. Donald Trump is leaving open the possibility he'll step into the fighting between Israel and Iran. New Zealand has paused its core sector support funding for the Cook Islands after its government signed partnership agreements with China earlier this year. Magic mushroom drug psilocybin will soon be available for patients with treatment-resistant depression. And we cross to Australia for our weekly chat with Kerry-Anne Walsh.
Scoop
6 hours ago
- Scoop
17,096 Kiwis Call For Urgent Action To Fund Keytruda For New Zealand's 'deadliest Breast Cancer'
Breast Cancer Foundation NZ is proud to support Auckland woman, Catherine Cooke, as she presents her petition to MP Hon. Mark Mitchell, urging the Government to fund the cancer drug Keytruda for early stage triple negative breast cancer (TNBC). Catherine is presenting the petition at Breast Cancer Foundation NZ office in Parnell on 27 June at 2pm. The level of support for this petition is significant and shows New Zealanders are fed up with falling behind the rest of the world in terms of access to life-saving treatment. Catherine was diagnosed with early TNBC, an aggressive form of breast cancer in November last year after her yearly mammogram. She was told Keytruda with chemotherapy would give her the best chance of survival – but the drug would only be funded if her cancer was advanced. Instead, Catherine has had to put most of her work on hold and sell her family home to fund the treatment - which is costing around $85,000. Around 350 women are diagnosed with triple negative breast cancer every year, which is approximately 10% of all breast cancer diagnoses. It is also more common in younger women with nearly 15% of diagnoses in women under the age of 45 being triple negative. For one in three women with early triple negative breast cancer, it will return and become incurable within five years. It is the deadliest form of breast cancer and is harder to treat. Unlike most other breast cancers, triple negative breast cancer doesn't respond to hormone-blocking treatments and targeted drugs. Keytruda is an immunotherapy drug, and it is the only targeted treatment that works to fight triple negative breast cancer and is given to patients alongside chemotherapy. It's fully funded in 40 other countries including Australia, Canada and Britain. New international research was published last year and showed that Keytruda can stop women dying from triple negative breast cancer because it's highly effective at preventing cancer coming back. Patients with early triple negative breast cancer receiving Keytruda in a clinical trial were 34% less likely to die and 32% less likely to have their cancer spread beyond the breast. It is widely accepted by the medical community internationally as the best drug to treat early triple negative breast cancer and New Zealanders deserve access to this treatment. Breast Cancer Foundation NZ Chief Executive, Ah-Leen Rayner said 'women like Catherine are having to go through drastic lengths to be able to pay for Keytruda. It's atrocious that New Zealanders are selling their homes, asking for help from their parents or complete strangers to find hundreds of thousands of dollars, or potentially simply going without treatment that could save their lives. 'We are so grateful to Catherine for working tirelessly for better drug access for New Zealanders in the future, but she shouldn't have to. We're urging the government to ensure Pharmac has the budget it needs to fund these essential medicines that are standard of care around the world.'
